MX345544B - Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba). - Google Patents

Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).

Info

Publication number
MX345544B
MX345544B MX2013004814A MX2013004814A MX345544B MX 345544 B MX345544 B MX 345544B MX 2013004814 A MX2013004814 A MX 2013004814A MX 2013004814 A MX2013004814 A MX 2013004814A MX 345544 B MX345544 B MX 345544B
Authority
MX
Mexico
Prior art keywords
ligands
triazole derivatives
gaba receptors
present
compounds
Prior art date
Application number
MX2013004814A
Other languages
English (en)
Other versions
MX2013004814A (es
Inventor
Thomas Andrew
Deems Gabriel Stephen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013004814A publication Critical patent/MX2013004814A/es
Publication of MX345544B publication Critical patent/MX345544B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de triazol de fórmula (I) en donde A, X, Y, u,v, R1, R2, y R3 son como se describen en la presente, así como también sales de los mismos farmacéuticamente aceptables. Los compuestos activos de la presente invención tienen afinidad y selectividad para el receptor GABA A a5. Además, la presente invención está relacionada con la manufactura de compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos.
MX2013004814A 2010-11-09 2011-11-02 Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba). MX345544B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190548 2010-11-09
PCT/EP2011/069192 WO2012062623A1 (en) 2010-11-09 2011-11-02 Triazole derivatives as ligands for gaba receptors

Publications (2)

Publication Number Publication Date
MX2013004814A MX2013004814A (es) 2013-06-28
MX345544B true MX345544B (es) 2017-02-03

Family

ID=44913272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004814A MX345544B (es) 2010-11-09 2011-11-02 Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).

Country Status (12)

Country Link
US (1) US8697696B2 (es)
EP (1) EP2638035B1 (es)
JP (1) JP5919291B2 (es)
KR (1) KR20130100348A (es)
CN (1) CN103189370B (es)
BR (1) BR112013011265A2 (es)
CA (1) CA2815741A1 (es)
ES (1) ES2536667T3 (es)
HK (1) HK1182101A1 (es)
MX (1) MX345544B (es)
RU (1) RU2582337C2 (es)
WO (1) WO2012062623A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014001280A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP6223443B2 (ja) * 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2014001278A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
EP4126858A1 (en) 2020-03-26 2023-02-08 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
CN115461337A (zh) 2020-05-13 2022-12-09 豪夫迈·罗氏有限公司 作为GABA A α5 PAM的新型三唑基衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229011A1 (de) * 1986-01-06 1987-07-15 Ciba-Geigy Ag Trisubstituierte Triazole
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
ATE371659T1 (de) * 1998-10-16 2007-09-15 Merck Sharp & Dohme Pyrazolotriazinderivate als gaba-rezeptorliganden
EP1129094A2 (en) * 1998-11-12 2001-09-05 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
RU2006127575A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
TW200533346A (en) * 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
JP5225984B2 (ja) * 2006-05-24 2013-07-03 イーライ リリー アンド カンパニー Ｆｘｒを調節する化合物及び方法
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
TWI472523B (zh) * 2008-06-19 2015-02-11 Takeda Pharmaceutical 雜環化合物及其用途
WO2010127975A1 (en) * 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
EP2298296A1 (en) * 2009-08-25 2011-03-23 CNRS Centre National De La Recherche Scientifique Composition and method for treating cognitive impairments in down syndrome subjects

Also Published As

Publication number Publication date
KR20130100348A (ko) 2013-09-10
ES2536667T3 (es) 2015-05-27
EP2638035B1 (en) 2014-12-17
US8697696B2 (en) 2014-04-15
US20120115868A1 (en) 2012-05-10
RU2582337C2 (ru) 2016-04-27
CN103189370A (zh) 2013-07-03
EP2638035A1 (en) 2013-09-18
JP2013542234A (ja) 2013-11-21
HK1182101A1 (en) 2013-11-22
JP5919291B2 (ja) 2016-05-18
BR112013011265A2 (pt) 2016-11-01
CN103189370B (zh) 2015-07-08
WO2012062623A1 (en) 2012-05-18
MX2013004814A (es) 2013-06-28
RU2013125338A (ru) 2014-12-20
CA2815741A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
MX347706B (es) Derivados de triazol y su uso para trastornos neurologicos.
MX2011011484A (es) Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
IN2012DN02465A (es)
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MY173448A (en) Phenyl and benzodioxinly substituted indazoles derivatives
MX2011007737A (es) Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a.
MX2011007772A (es) Derivados de isoxazol/o-piridina con enlazador etilo y etenilo.
MX2011011303A (es) Derivados de isoxazol.
MY183312A (en) Pharmaceutical formulation
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
MX2013008531A (es) Nuevos compuestos de benzodioxol-piperazina.
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
MX2013005966A (es) Nuevos compuestos de benzofurano.
MX342824B (es) Nuevos compuestos de triazol iii.
MY156731A (en) NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES
MX2013011728A (es) Nuevos compuestos de benzofurano-piperidina.

Legal Events

Date Code Title Description
FG Grant or registration